Bruna Viana Barroso Martins

Mrs. Bruna Viana Barroso Martins


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2025 in Toxicon: X
Verified
Journal Article
Open access
NLNicole Coelho Lopes
Nicole Coelho Lopes
GMGdayllon Cavalcante Meneses
Gdayllon Cavalcante Meneses
RSRanieri Sales de Souza Santos
Ranieri Sales de Souza Santos
LALeticia Machado de Araújo
Leticia Machado de Araújo
BMBruna Viana Barroso Martins
Bruna Viana Barroso Martins
AMAlice Maria Costa Martins
Alice Maria Costa Martins
Snakebite antivenom (SAV) is the standard treatment option to neutralize the toxic effects of snake venom, but their consequences on kidney function need to be better understood. This study aims to evaluate the effects of antivenom on kidney and endothelial biomarkers due to Bothrops venom in two subgroups of patients distinguished by the presence of hemorrhagic syndrome at admission. This prospective study included 34 snakebite patients admitted to a tertiary hospital in Northeast Brazil between August 2019 and November 2020, 50 % of whom experienced spontaneous bleeding. Endothelial and kidney damage biomarkers were analyzed at three time points: before antivenom infusion and after 10 h and 20 h of antivenom infusion. Bleeding patients exhibited higher urine Neutrophil Gelatinase-Associated Lipocalin (uNGAL) and Kidney Injury Molecule-1 (KIM-1) levels, indicating incomplete renal recovery until 20h after antivenom. This group showed higher serum angiopoietin-2 (Ang-2) levels and vascular cell adhesion molecule-1 (VCAM-1). VCAM-1 levels positively correlated with kidney biomarker levels at each time point, especially after SAV. uNGAL was variant across VCAM-1, Ang-1, and Ang-2 levels before antivenom. Elevated levels of uNGAL and KIM-1, observed 10 h after SAV administration, may indicate incomplete renal protection and a potential risk for the development of chronic kidney injury, requiring future follow-up.

23 February 2026 in Toxins
Verified
Journal Article
Open access
PDF file
NLNicole Coelho Lopes
Nicole Coelho Lopes
RSRanieri Sales de Souza Santos
Ranieri Sales de Souza Santos
GMGdayllon Cavalcante Meneses
Gdayllon Cavalcante Meneses
LALeticia Machado de Araújo
Leticia Machado de Araújo
BMBruna Viana Barroso Martins
Bruna Viana Barroso Martins
AMAlice Maria Costa Martins
Alice Maria Costa Martins
Bothrops snakebites pose a significant public health challenge in low- and middle-income regions, often resulting in inflammation, coagulopathy, and renal complications even after antivenom therapy. This study investigated the role of interleukin-33 (IL-33) and endothelial biomarkers in patients with Bothrops envenoming to better understand the mechanisms associated with bleeding and kidney dysfunction. In a prospective cohort of 31 patients from Northeast Brazil, serum levels of IL-33, von Willebrand factor A2 (vWF-A2), angiopoietin-1, angiopoietin-2, syndecan-1, and VCAM-1 were measured at admission and at 10 and 20 h after antivenom administration. Fourteen patients (45%) presented with bleeding at baseline. Traditional clinical and laboratory parameters did not differ between the bleeding and non-bleeding groups on admission; however, IL-33 levels were significantly higher in patients with bleeding. Elevated IL-33 on admission correlated positively with vWF-A2 and estimated glomerular filtration rate, and negatively with angiopoietin-1, suggesting links between inflammation, endothelial dysfunction, and early renal involvement. IL-33 showed a good performance in bleeding patients (AUC = 0.739; IC 95% 0.562–0.917). These findings identified the link between IL-33, early hemorrhage, endothelial dysfunction, and renal involvement in acute Bothrops envenoming. After antivenom therapy, IL-33 levels presented dynamic changes in all patients and require further studies.